Clinical trials investigating the macular carotenoids

Sarah Sabour-Pickett; John M. Nolan; Stephen Beatty

doi:10.1201/b15556

Clinical trials investigating the macular carotenoids

Sarah Sabour-Pickett, John M. Nolan, Stephen Beatty

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Citation (Scopus)

Abstract

The anatomical (central retinal), biochemical (antioxidant), and optical (short-wavelength filtering) properties of macular pigment (MP) have generated interest in the biologically plausible rationale that MP may not only confer protection against age-related macular degeneration (AMD) but also optimize vision. The testing of this hypothesis has been a subject of growing interest over the past decade. This chapter reviews the evidence from the clinical trials that have investigated the role of macular carotenoid supplementation on macular pigment optical density (MPOD), on visual performance, and on the risk of disease progression in subjects afflicted with AMD. In addition, the more recent studies investigating the impact of supplementation with the macular carotenoids on visual performance in normal subjects (without disease) will be discussed.

Original language	English
Title of host publication	Carotenoids and Retinal Disease
Publisher	CRC Press
Pages	75-91
Number of pages	17
ISBN (Electronic)	9781466502055
ISBN (Print)	9781466502048
DOIs	https://doi.org/10.1201/b15556
Publication status	Published - 01 Jan 2013

Access to Document

10.1201/b15556

Cite this

@inbook{56a72573fcb942079b47c2e4cdf948eb,

title = "Clinical trials investigating the macular carotenoids",

abstract = "The anatomical (central retinal), biochemical (antioxidant), and optical (short-wavelength filtering) properties of macular pigment (MP) have generated interest in the biologically plausible rationale that MP may not only confer protection against age-related macular degeneration (AMD) but also optimize vision. The testing of this hypothesis has been a subject of growing interest over the past decade. This chapter reviews the evidence from the clinical trials that have investigated the role of macular carotenoid supplementation on macular pigment optical density (MPOD), on visual performance, and on the risk of disease progression in subjects afflicted with AMD. In addition, the more recent studies investigating the impact of supplementation with the macular carotenoids on visual performance in normal subjects (without disease) will be discussed.",

author = "Sarah Sabour-Pickett and Nolan, {John M.} and Stephen Beatty",

note = "Publisher Copyright: {\textcopyright} 2014 by Taylor & Francis Group, LLC.",

year = "2013",

month = jan,

day = "1",

doi = "10.1201/b15556",

language = "English",

isbn = "9781466502048",

pages = "75--91",

booktitle = "Carotenoids and Retinal Disease",

publisher = "CRC Press",

address = "United States",

}

TY - CHAP

T1 - Clinical trials investigating the macular carotenoids

AU - Sabour-Pickett, Sarah

AU - Nolan, John M.

AU - Beatty, Stephen

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The anatomical (central retinal), biochemical (antioxidant), and optical (short-wavelength filtering) properties of macular pigment (MP) have generated interest in the biologically plausible rationale that MP may not only confer protection against age-related macular degeneration (AMD) but also optimize vision. The testing of this hypothesis has been a subject of growing interest over the past decade. This chapter reviews the evidence from the clinical trials that have investigated the role of macular carotenoid supplementation on macular pigment optical density (MPOD), on visual performance, and on the risk of disease progression in subjects afflicted with AMD. In addition, the more recent studies investigating the impact of supplementation with the macular carotenoids on visual performance in normal subjects (without disease) will be discussed.

AB - The anatomical (central retinal), biochemical (antioxidant), and optical (short-wavelength filtering) properties of macular pigment (MP) have generated interest in the biologically plausible rationale that MP may not only confer protection against age-related macular degeneration (AMD) but also optimize vision. The testing of this hypothesis has been a subject of growing interest over the past decade. This chapter reviews the evidence from the clinical trials that have investigated the role of macular carotenoid supplementation on macular pigment optical density (MPOD), on visual performance, and on the risk of disease progression in subjects afflicted with AMD. In addition, the more recent studies investigating the impact of supplementation with the macular carotenoids on visual performance in normal subjects (without disease) will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=85031319477&partnerID=8YFLogxK

U2 - 10.1201/b15556

DO - 10.1201/b15556

M3 - Chapter

AN - SCOPUS:85031319477

SN - 9781466502048

SP - 75

EP - 91

BT - Carotenoids and Retinal Disease

PB - CRC Press

ER -

Clinical trials investigating the macular carotenoids

Abstract

Access to Document

Other files and links

Fingerprint

Cite this